Adrenergic modulation of human pancreatic polypeptide (hPP) release. 1980

A A Sive, and A I Vinik, and N Levitt

Serum human pancreatic polypeptide (hPP) responses to adrenergic modulation were measured in 24 normal subjects. Epinephrine (6 microgram/min) was infused to stimulate adrenergic alpha- and beta-receptors. Beta-receptor stimulation was achieved by infusing epinephrine and selectively blocking alpha- receptors with phentolamine, and alpha-receptor stimulation was achieved by infusing epinephrine and blocking beta-receptors with propranolol. Combined alpha- and beta-receptor stimulation caused a small but insignificant rise in hPP concentration. Phentolamine alone caused a twofold rise in hPP concentration, which was abolished by simultaneous atropine infusion. Propranolol alone had no effect. Adrenergic beta-receptor stimulation with epinephrine plus phentolamine caused a sevenfold rise from 45 +/- 10 to 351 +/- 60 pM (P < 0.05), whereas adrenergic alpha-receptor stimulation caused a significant fall from 100 +/- 25 pM (the rise in hPP concentration induced by epinephrine) to 44 +/- 7.8 pM. The changes in hPP concentration did not correlate with changes in serum insulin, glucose, or free fatty acid (FFA) concentrations. The pattern of the response was quite different from insulin, while reached a peak within 1 min of phentolamine administration, whereas hPP levels rose slowly to a peak at 45 min. The rise induced by adrenergic beta-receptor stimulation with epinephrine plus phentolamine was equivalent to the rise from 40 +/- 11 to 280 +/- 48 pM caused by an insulin-induced fall in serum glucose of about 50% and that induced by isoproterenol infusion, which caused a fourfold rise from 69 +/- 3 to 271 +/- 84 pM. These data suggest that the adrenergic system may be important in the regulation of hPP release.

UI MeSH Term Description Entries
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010191 Pancreatic Polypeptide A 36-amino acid pancreatic hormone that is secreted mainly by endocrine cells found at the periphery of the ISLETS OF LANGERHANS and adjacent to cells containing SOMATOSTATIN and GLUCAGON. Pancreatic polypeptide (PP), when administered peripherally, can suppress gastric secretion, gastric emptying, pancreatic enzyme secretion, and appetite. A lack of pancreatic polypeptide (PP) has been associated with OBESITY in rats and mice. Pancreatic Polypeptide (PP),Pancreatic Polypeptide Hormone,Pancreatic Prohormone
D010646 Phentolamine A nonselective alpha-adrenergic antagonist. It is used in the treatment of hypertension and hypertensive emergencies, pheochromocytoma, vasospasm of RAYNAUD DISEASE and frostbite, clonidine withdrawal syndrome, impotence, and peripheral vascular disease. Fentolamin,Phentolamine Mesilate,Phentolamine Mesylate,Phentolamine Methanesulfonate,Phentolamine Mono-hydrochloride,Regitine,Regityn,Rogitine,Z-Max,Mesilate, Phentolamine,Mesylate, Phentolamine,Methanesulfonate, Phentolamine,Mono-hydrochloride, Phentolamine,Phentolamine Mono hydrochloride
D011433 Propranolol A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs. Dexpropranolol,AY-20694,Anaprilin,Anapriline,Avlocardyl,Betadren,Dociton,Inderal,Obsidan,Obzidan,Propanolol,Propranolol Hydrochloride,Rexigen,AY 20694,AY20694,Hydrochloride, Propranolol
D011941 Receptors, Adrenergic Cell-surface proteins that bind epinephrine and/or norepinephrine with high affinity and trigger intracellular changes. The two major classes of adrenergic receptors, alpha and beta, were originally discriminated based on their cellular actions but now are distinguished by their relative affinity for characteristic synthetic ligands. Adrenergic receptors may also be classified according to the subtypes of G-proteins with which they bind; this scheme does not respect the alpha-beta distinction. Adrenergic Receptors,Adrenoceptor,Adrenoceptors,Norepinephrine Receptor,Receptors, Epinephrine,Receptors, Norepinephrine,Adrenergic Receptor,Epinephrine Receptors,Norepinephrine Receptors,Receptor, Adrenergic,Receptor, Norepinephrine
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D004837 Epinephrine The active sympathomimetic hormone from the ADRENAL MEDULLA. It stimulates both the alpha- and beta- adrenergic systems, causes systemic VASOCONSTRICTION and gastrointestinal relaxation, stimulates the HEART, and dilates BRONCHI and cerebral vessels. It is used in ASTHMA and CARDIAC FAILURE and to delay absorption of local ANESTHETICS. Adrenaline,4-(1-Hydroxy-2-(methylamino)ethyl)-1,2-benzenediol,Adrenaline Acid Tartrate,Adrenaline Bitartrate,Adrenaline Hydrochloride,Epifrin,Epinephrine Acetate,Epinephrine Bitartrate,Epinephrine Hydrochloride,Epinephrine Hydrogen Tartrate,Epitrate,Lyophrin,Medihaler-Epi,Acetate, Epinephrine
D005230 Fatty Acids, Nonesterified FATTY ACIDS found in the plasma that are complexed with SERUM ALBUMIN for transport. These fatty acids are not in glycerol ester form. Fatty Acids, Free,Free Fatty Acid,Free Fatty Acids,NEFA,Acid, Free Fatty,Acids, Free Fatty,Acids, Nonesterified Fatty,Fatty Acid, Free,Nonesterified Fatty Acids

Related Publications

A A Sive, and A I Vinik, and N Levitt
March 1995, Nihon rinsho. Japanese journal of clinical medicine,
A A Sive, and A I Vinik, and N Levitt
December 1999, Nihon rinsho. Japanese journal of clinical medicine,
A A Sive, and A I Vinik, and N Levitt
January 1986, Minerva endocrinologica,
A A Sive, and A I Vinik, and N Levitt
January 1986, Acta physiologica Hungarica,
A A Sive, and A I Vinik, and N Levitt
August 1980, Metabolism: clinical and experimental,
A A Sive, and A I Vinik, and N Levitt
January 1981, Scandinavian journal of gastroenterology,
A A Sive, and A I Vinik, and N Levitt
August 1979, Clinical biochemistry,
A A Sive, and A I Vinik, and N Levitt
January 1975, Cell and tissue research,
A A Sive, and A I Vinik, and N Levitt
October 1976, Gut,
Copied contents to your clipboard!